Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 663.15 INR
Change Today -19.00 / -2.79%
Volume 2.8M
CIPLA On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:05 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

cipla ltd (CIPLA) Snapshot

Open
682.00
Previous Close
682.15
Day High
688.20
Day Low
657.00
52 Week High
03/10/15 - 752.85
52 Week Low
09/2/14 - 532.10
Market Cap
532.6B
Average Volume 10 Days
3.2M
EPS TTM
14.71
Shares Outstanding
803.1M
EX-Date
08/11/15
P/E TM
45.1x
Dividend
2.00
Dividend Yield
0.30%
Current Stock Chart for CIPLA LTD (CIPLA)

Related News

No related news articles were found.

cipla ltd (CIPLA) Related Businessweek News

No Related Businessweek News Found

cipla ltd (CIPLA) Details

Cipla Limited manufactures and sells pharmaceutical and personal care products in India. It offers active pharmaceutical ingredients; and formulations in therapeutic areas, such as allergy, analgesic, anti-malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, oncology, respiratory, urology, and women’s health, as well as nutritional and ophthalmic products. The company also provides veterinary products for various animals, including companion, equine, general care, livestock, and poultry. In addition, it offers inhaled medication and devices comprising dry powder inhalers, metered-dose inhalers, spacers and related devices, nasal sprays, nebulizers, and inhalation accessory devices. The company also exports raw materials, intermediates, prescription drugs, over-the-counter drugs, and veterinary products to approximately 170 countries worldwide. Cipla Limited was founded in 1935 and is based in Mumbai, India.

Founded in 1935

cipla ltd (CIPLA) Top Compensated Officers

Global Chief Executive Officer, Managing Dire...
Total Annual Compensation: 54.4M
Whole-Time Director, Member of Mergers & Acqu...
Total Annual Compensation: 12.0M
Chief Compliance Officer and Company Secretar...
Total Annual Compensation: 9.5M
Compensation as of Fiscal Year 2015.

cipla ltd (CIPLA) Key Developments

Cipla Limited Reports Audited Consolidated Cash Flow Results for the Year Ended March 31, 2015

Cipla Limited reported audited consolidated cash flow results for the year ended March 31, 2015. For the period, the company reported net cash from operating activities of INR 10,514.1 million against INR 18,124.8 million a year ago. Purchase of fixed assets/capital work-in-progress and intangibles was INR 5,326.3 million against INR 5,020.3 million a year ago.

Cipla Appoints Prabir Jha as HR Head

Prabir Jha, who has recently quit Reliance Industries as its chief human resources officer, is reportedly considering an offer to join Cipla as head human resources. Jha, had joined RIL two years ago and was instrumental in several progressive HR measures including a five-day week, increased leave entitlements, extension of maternity leave and several other changes to simplify policies. Jha had joined RIL from Tata Motors.

Cipla Reportedly Mulls Acquisition Of Stake In Kremers

Cipla Limited (NSEI:CIPLA) reportedly seeking acquisition of stakes in Kremers Urban Pharmaceuticals Inc. from UCB S.A. (ENXTBR:UCB). Cipla has emerged as the sole Indian contender for Kremers Urban Pharmaceuticals Inc. which is pegged at around $1.3 billion. "Cipla is the only Indian bidder for KU but it is pitted against a few powerful private equity players. It also depends on whether Cipla is prepared to shell out a large amount in a single bid," an industry watcher told Economic Times. Lupin Limited (BSE:500257) and Torrent Pharmaceuticals Ltd. (BSE:500420) were named as the other two Indian parties that had initially shown interest but eventually opted out. One of them is China's conglomerate China Grand Group. UCB floated the divestiture of Kremers Urban in 2014. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. Kremers had sales of $463 million in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIPLA:IN 663.15 INR -19.00

CIPLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 737.75 INR -15.25
Cadila Healthcare Ltd 1,879 INR -19.40
Piramal Enterprises Ltd 936.65 INR -37.20
Torrent Pharmaceuticals Ltd 1,636 INR +28.80
Wockhardt Ltd 1,294 INR -48.10
View Industry Companies
 

Industry Analysis

CIPLA

Industry Average

Valuation CIPLA Industry Range
Price/Earnings 34.5x
Price/Sales 4.2x
Price/Book 4.9x
Price/Cash Flow 25.8x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPLA LTD, please visit www.cipla.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.